Abbvie Reports Two Years Data of Skyrizi (risankizumab) in P-III IMMhance Study for Moderate to Severe Plaque Psoriasis #WCD2019

Abbvie Reports Two Years Data of Skyrizi (risankizumab) in P-III IMMhance Study for Moderate to Severe Plaque Psoriasis #WCD2019

Shots:

  • The P-III IMMhance study results involves assessing of Skyrizi (SC, 150mg) vs PBO in patients in a ratio (4:1) for moderate to severe plaque psoriasis for 2yrs.
  • The P-III IMMhance study results: @94wk. complete skin clearance; sPGA 0 (73%); PASI 100 (72%); @16wks. met 1EPs of the first phase of the study; @52wks. met 1EPs of the second phase of the study; sPGA 0 and PASI 100, @55 & 94wks. (65% and 64% & 73% and 72%); @2yrs (81% and 78% vs 7% and 4%) re-randomized to withdrawal patients respectively
  • Skyrizi is an IgG1 mAb targeting IL-23, inhibiting its binding with p19 subunit and has received EU’s approval for moderate to severe plaque psoriasis in adults who are candidates for systemic therapy

Click here to read full press release/ article | Ref: Abbvie | Image: EFA